Project Grant R44AI179506

The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $292,746 Cooperative Agreement to Tsrl, Inc. (doing business as Therapeutic Systems Research Laboratories), a woman-owned small business located in Ann Arbor, Michigan. The purpose of this award is to conduct a Phase 1 clinical trial to assess the pharmacokinetics, safety, and tolerance of a zanamivir transdermal system in healthy subjects. This...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $390,942 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Georgia Tech Research Corp to develop self-assembled peptide nanoparticles as a universal influenza vaccine platform. The goal is to use these nanoparticles to present conserved viral antigens, including hemagglutinin stalk, matrix protein 2 ectodomain, and nucleoprotein, in order to elicit broad, protective immune...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded Orlance, Inc., a woman-owned small business, a $300,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop an enhanced seasonal influenza DNA vaccine. The project aims to combine the advantages of a closely matched seasonal influenza vaccine with a universal influenza vaccine to provide more robust and durable protection, especially for the elderly and immunocompromised...

The Defense Health Agency awarded Flugen Inc. a $6,237,445 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to optimize downstream recovery and stabilization of the drug substance for their intranasal influenza vaccine. The three-year grant also supports research on concurrent administration of Flugen's H3N2 M2SR monovalent influenza vaccine with inactivated flu vaccines in older adult populations. This award builds on Flugen's previous federal grants...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $3,170,096.00 to New York University School of Medicine to develop and optimize a peptide inhibitor of influenza virus splicing for broad-spectrum antiviral therapy. The key objectives are: (1) investigating the mechanism of action of the L7AE protein on various Orthomyxoviridae family members, (2) characterizing a transgenic mouse...

This $788,406 project grant from the National Institutes of Health National Institute of Allergy and Infectious Diseases, under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund the development of a sensitive, direct reading bioaerosol detection platform to quantify airborne pathogens such as SARS-CoV-2. Aerosol Devices Inc. will integrate their gentle condensation-growth capture sampler, which concentrates intact, viable virus particles into a small liquid volume...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $239,120 to Trustees of Tufts College (Tufts University School of Medicine) to conduct research on analyzing the heterogeneity of cell death responses in influenza virus-infected cells. The research aims to elucidate the interplay between transcriptional and cell death responses during influenza infection, using a...

This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to elucidate the mechanisms by which influenza infection can protect against malaria-associated respiratory distress syndrome (MA-ARDS) in mice. The $224,070 award to the University of Utah aims to determine how influenza modifies pulmonary vascular endothelial cells and induces arginase 1-producing...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $184,375 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Florida International University (FIU) to optimize a novel antimicrobial peptide, A4-X7, for pulmonary delivery to combat antimicrobial-resistant respiratory infections. The funded research aims to prepare, characterize, and evaluate the antimicrobial and antibiofilm activities of the A4-X7 formulation for aerosolized...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $722,958 to the University of Rochester to investigate the role of monocyte-derived galectin-1 in promoting tissue-resident memory T cell responses against influenza virus. The research aims to (1) study monocyte differentiation during immune memory formation after influenza infection, (2) determine how galectin-1...